Ain-Shams University Hospitals
Cairo, 11361, Egypt
NCT Number: NCT05539027
One of the most significant goals of hepatic encephalopathy (HE) treatment is to reduce ammonia levels by lowering its synthesis and enhancing its detoxification which can be achieved by using non-absorbable disaccharides, antibiotics, branched-chain amino acids (BCAA), L-ornithine L-aspartate (LOLA), and probiotics.
LOLA decreases ammonia, therefore, it is presumed to decrease agitated delirium in HE patients and thus decrease their need for other sedatives. On the other hand, BCAA improve mental function in HE patients by increasing the detoxification of ammonia in muscles.
Looking for future studies?
Notify Me21 year–70 year
All sexes
Interventional
Phase 4
Cairo, 11361, Egypt
The most often utilized criteria for grading HE are the West Haven criteria (WHC). This grading distinguishes four levels of clinically evident hepatic encephalopathy.
West Haven criteria (WHC): [R]
Stage Consciousness
REFERENCES:
Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
patients will receive branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)
patients will receive BCAA enriched solution (Aminoleban)
Time frame: 5 days of treatment
Reversal of Hepatic encephalopathy or change of Hepatic encephalopathy by two grades (according to West Havens Criteria)
Ain Shams University
Other
Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy: a Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05425316
Brain Diseases, Brain Diseases, Metabolic
Ann Arbor, Michigan, United States
View Trial DetailsNCT07480096
Brain Diseases, Brain Diseases, Metabolic
Jakarta, DKI Jakarta, Indonesia
View Trial DetailsNCT05754996
Brain Diseases, Brain Diseases, Metabolic
Cairo, Egypt
View Trial DetailsNCT05070351
Brain Diseases, Brain Diseases, Metabolic
Durham, North Carolina, United States
View Trial Details